^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lymphoma

    Related cancers:
    1d
    Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma (clinicaltrials.gov)
    P=N/A, N=144, Recruiting, University Health Network, Toronto | N=80 --> 144 | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    1d
    KSV01 Injection for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=30, Recruiting, TCRx Therapeutics Co.Ltd
    New P1 trial
    1d
    Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial (clinicaltrials.gov)
    P3, N=668, Recruiting, University of Rochester | Phase classification: P=N/A --> P3 | N=960 --> 668 | Trial completion date: Dec 2028 --> May 2027 | Trial primary completion date: Jun 2028 --> May 2027
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    1d
    Virtual Rehabilitation for Cancer Survivors (clinicaltrials.gov)
    P=N/A, N=388, Recruiting, University Health Network, Toronto | Trial completion date: Aug 2025 --> Nov 2026 | Trial primary completion date: May 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    1d
    WF-1804CD: Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors (clinicaltrials.gov)
    P=N/A, N=600, Completed, Wake Forest University Health Sciences | Active, not recruiting --> Completed
    Trial completion
    1d
    Acquired MYC rearrangement potentially associated with ibrutinib resistance in mantle cell lymphoma. (PubMed, Virchows Arch)
    In conclusion, our findings suggest that c-Myc overexpression and MYC rearrangement are associated with ibrutinib resistance in MCL. Detecting MYC rearrangement in selected MCL cases could be critical for optimizing treatment strategies and improving patient outcomes.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11)
    |
    Imbruvica (ibrutinib)
    1d
    A Novel Prognostic Model for Primary CNS Lymphoma Incorporating Clinico-Laboratory Parameters. (PubMed, Neuro Oncol)
    The ABLE risk-stratification model can effectively differentiate prognostic subgroups in patients with PCNSL.
    Journal
    |
    B2M (Beta-2-microglobulin)
    |
    methotrexate • methotrexate IV
    1d
    Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial. (PubMed, Lancet Haematol)
    An intensification strategy guided by response and MRD deepened remissions in individuals with residual disease and spared early responders further treatment. This approach merits further study as an alternative to fixed-duration triplet therapy.
    P2 data • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)
    1d
    Reveal the regulatory role of DDX10 in diffuse large B-cell lymphoma: binding with FBL to promote cell proliferation and invasion. (PubMed, Mol Cell Probes)
    DDX10 contributes to the proliferation and invasion of DLBCL cells via positively regulating FBL, highlighting the DDX10-FBL axis as a potential therapeutic target. This work provides new insights into DLBCL pathogenesis and underscores the biomedical relevance of targeting DDX10-FBL.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • DDX1 (DEAD-Box Helicase 1) • DDX10 (DEAD-Box Helicase 10)
    1d
    Spatial transcriptomics uncovers unique tumor microenvironments in folliculotropic versus classic mycosis fungoides. (PubMed, J Invest Dermatol)
    These findings suggest the follicular microenvironment may provide survival advantages to malignant T cells while promoting a dysregulated anti-tumor immune response. These observations provide insight into the mechanisms underlying the more aggressive clinical features of FMF versus CMF.
    Journal
    |
    CD4 (CD4 Molecule) • IL2 (Interleukin 2)
    1d
    STAIR: STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, French Innovative Leukemia Organisation | Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2026 --> Aug 2025
    Enrollment closed • Trial primary completion date
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
    |
    TP53 mutation • IGH mutation
    |
    Calquence (acalabrutinib)
    1d
    Comparative Study of Transaxillary Robotic Thyroidectomy With MRND Versus Conventional Open Surgery in N1b PTC (clinicaltrials.gov)
    P=N/A, N=876, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting --> Recruiting
    Enrollment open